Semaglutide
A GLP-1 receptor agonist with controlled clinical evidence for specific approved uses, where product status, jurisdiction, and formulation matter.
Last reviewed:
- Studies
- 0
- Tracked suppliers
- 0
- Identifiers
- 3
- Updated
- Jul 28, 2026
Identity
Overview
- Aliases
- GLP-1 receptor agonist
- Topics
- clinical medicine, glp-1, metabolic, metabolism
- Formula
- C187H291N45O59
- Sequence
- Modified GLP-1 receptor agonist peptide
- Regulatory and product note
- Separate approved-product evidence, research evidence, and supplier product claims.
Proposed mechanism
Proposed mechanism
Discussed around GLP-1 receptor signaling, appetite regulation, glycemic control, gastric emptying, and metabolic outcomes.
Evidence
Evidence and limitations
This record keeps mechanisms, animal studies, human biomarkers, controlled clinical outcomes, safety data, and supplier documentation separate so claims are not flattened into one misleading score.
Research questions tracked
- What exact molecule, route, formulation, and outcome were studied?
- Is the evidence mechanistic, animal, early human, or controlled clinical evidence?
- Does the commercial product match the studied material and documentation?
Key findings and boundaries
- Evidence strength changes by outcome and study type.
- Mechanism is useful context but not proof of clinical benefit.
- Supplier claims require separate documentation review.
Important gaps
- Long-term human safety and real-world product quality are often incomplete.
- Claims can exceed the route, formulation, and population studied.
Safety and unknowns
Safety and unknowns
Approved-medicine evidence cannot be transferred to every compounded, research, or supplier-marketed product using related language.
- Known and plausible adverse effects must be separated from product-quality risks.
- Injectable or research-use products add sterility, endotoxin, impurity, and handling concerns.
Testing & COAs
Testing and COAs
An observed COA may support specific laboratory findings. It does not by itself prove clinical benefit, safety, legality, sterility or suitability.
- Identity, assay/purity, batch matching, lab identity, and test date should be visible.
- COAs do not prove clinical effectiveness, legal status, or suitability for use.